Business Wire

CA-PSMF

2.6.2023 08:16:30 CEST | Business Wire | Press release

Share
10th Annual World Patient Safety, Science & Technology Summit Begins

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)

Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospitals. We’re all humans, we’re all a little bit competitive, and I think you react to data. This will make a difference.”

In a keynote address, Don Berwick, MD, MPP, FRCP, former administrator of the Centers for Medicare and Medicaid Services, pointed out that one in four hospital patients experience injury as a result of their care.

“Healthcare is far too unsafe,” said Berwick. “A large proportion of patient safety problems can be eliminated. There are hospitals in this nation that have driven certain kinds of infections to zero and virtually eliminated the risk of pneumonia from ventilation machines.”

Berwick suggested that healthcare systems can learn from many of the safety practices that the aviation industry has successfully put in place. “Today, you would have to fly continuously on a commercial flight for over 6,000 years to have a 50:50 chance of being injured as a passenger,” he said. “Roughly speaking, that means you are more than two million times safer in an airplane seat than in a hospital.”

Jannicke Mellin-Olsen, former president of the World Federation of Societies of Anesthesiologists, used her keynote address to call for more healthcare systems to involve patients and family members of those who have suffered harm in order to help drive better practices. “Involvement means hearing the patient voice at every level of the service,” she said.

The first day of the Summit also featured a talk from Sir Liam Donaldson, former chief medical officer of the United Kingdom, who discussed the impact of Covid-19 on patient safety and how the pandemic illustrated the lack of resilience throughout our healthcare structures. “There wasn’t much thinking about patient safety in the pandemic planning that preceded Covid,” said Donaldson. “Failures to develop world-class infection control facilities put both health workers and patients at risk, but there was also the issue of transitions of care, which greatly affected elderly patients and led to the virus spreading through nursing homes. That should have been part of our thinking from a patient safety perspective.”

Neelam Dhingra, who heads the World Health Organization’s (WHO) Transformative Flagship Initiative, emphasized the need to improve patient safety in low- and middle-income countries. Dhingra pointed out how when WHO conducted a survey of 102 countries in 2022, just 27% had developed a national patient safety action plan, and only 18% had established national targets on reducing medication-related harm.

“In low- and middle-income countries, we are still very far from even simple procedures when it comes to patient safety,” said Dhingra. “Studies from these countries are limited, but the estimates we have suggest that every minute at least five patients die in hospital. This means that the burden of harm in healthcare is grossly underestimated.”

Konrad Reinhart, founding president of the Global Sepsis Alliance, highlighted the continuing need to improve public awareness on sepsis and push for hospitals to comply with best practices. “Given the number of sepsis deaths worldwide, which are higher than cancer, the potential to reduce harm is enormous,” he said.

There were additional talks from world-renowned patient safety champion Peter Pronovost, along with Stephanie Mercado, chief executive officer of the National Association for Healthcare Quality, and Peter Lachman who leads the PSMF’s Fellowship Program. Tedros Adhanom Ghebreyesus, director general of WHO, addressed the Summit in a prerecorded video message.

Panel discussions included contributions from members of the President’s Council of Advisors on Science and Technology regarding their upcoming report on patient safety, as well as an assessment from healthcare leaders on the potential of predictive analytics and AI to improve patient safety.

Other panels touched on subjects ranging from the need for patient and family engagement in healthcare to proposals for forming a National Patient Safety Board. The day’s program ended with a private screening of the HBO documentary Bleed Out.

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230601006140/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release

Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release

ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release

$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye